Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Satlin MJ, Goyal P, Magleby R, Maldarelli GA, Pham K, Kondo M, et al. Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease. PLoS One. 2020;15(7):e0236778.

van Daalen EE, Trejo MA, Göçeroğlu A, Ferrario F, Joh K, Noël L-, et al. Developments in the Histopathological Classification of ANCA-Associated Glomerulonephritis. Clin J Am Soc Nephrol. 2020;15(8):1103-1111.

Sung S, Heymann JJ, Crapanzano JP, Moreira AL, Shu C, Bulman WA, et al. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management. J Am Soc Cytopathol. 2020;9(5):332-345.

Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, et al. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab. 2020;2(10):1034-1045.

Lam HC, Baglini CV, Lope AL, Parkhitko AA, Liu H-, Alesi N, et al. Correction: p62/SQSTM1 Cooperates with Hyperactive mTORC1 to Regulate Glutathione Production, Maintain Mitochondrial Integrity, and Promote Tumorigenesis. Cancer Res. 2020;80(23):5424.

Usui J, Yaguchi M, Yamazaki S, Takahashi-Kobayashi M, Kawamura T, Kaneko S, et al. Transcription factor 21 expression in injured podocytes of glomerular diseases. Sci Rep. 2020;10(1):11516.

Haney NM, Faisal FA, Lu J, Guedes LB, Reuter VE, Scher HI, et al. Loss with Negative Status is Associated with Lethal Disease after Radical Prostatectomy. J Urol. 2020;203(2):344-350.

Venturutti L, Teater M, Zhai A, Chadburn A, Babiker L, Kim D, et al. TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020;182(2):297-316.e27.

Kim J-, Yang Y-, Park KH, Ge X, Xu R, Li N, et al. A RUNX2 stabilization pathway mediates physiologic and pathologic bone formation. Nat Commun. 2020;11(1):2289.

Sangiorgio VF, Geyer JT, Margolskee E, Al-Kawaaz M, Mathew S, Tam W, et al. Myeloid neoplasms with isolated del(5q) and V617F mutation: a "grey zone" combination of myelodysplastic and myeloproliferative features? Haematologica. 2020;105(6):e276-e279.